The Drug That Treats SMA's Muscle Problem, Not Just Its Genetic One

The approved label covers adults and children ages 2 and older who are already on an SMN-boosting treatment. That "already on" part is key: apitegromab is designed as an add-on, not a replacement. The recommended dose is 10 mg/kg.

The Data Behind the Green Light

The approval was built on the Phase 3 SAPPHIRE trial, which tested apitegromab in SMA patients already receiving background SMN-targeted therapy. The primary measure was the Hammersmith Functional Motor Scale-Expanded (HFMSE), a well-established test of motor function that scores things like sitting, standing, and walking ability.

The combined dose groups showed a 1.8-point improvement in HFMSE over placebo, hitting statistical significance with a p-value of 0.0192. For context in a disease where patients often plateau or slowly decline despite treatment, any upward movement on the motor scale is clinically meaningful.

The 10 mg/kg dose (which became the approved dose) performed even better, showing a 2.2-point advantage over placebo. And the responder analysis told an encouraging story: 30.4% of apitegromab patients gained at least 3 points on the HFMSE, compared to just 12.5% on placebo. That's nearly a 2.5x difference in the proportion of patients hitting a meaningful functional milestone.

Why Wall Street Is Unusually United

Analyst reactions ranged from bullish to very bullish, which is saying something for a small biotech. Scholar Rock had strong Buy-side consensus across its coverage universe.

Truist Securities bumped its price target to $76 from $55, citing expected broad patient uptake. Raymond James went to $72 from $65, projecting roughly $2.2 billion in apitegromab revenue by 2035. Citi lifted its target to $74 from $60. BMO called the label "broad" and pointed to visible physician demand.

Cantor Fitzgerald took the most aggressive stance, suggesting apitegromab could capture near-complete market share as the only muscle-building therapy in SMA. When you're the only restaurant on the block, you tend to get all the customers.

The company hadn't announced pricing as of the approval date, which means the commercial launch is the next chapter investors will be watching closely. Manufacturing hiccups or pricing missteps could dampen the enthusiasm, but for now, the Street is giving Scholar Rock a standing ovation.

The Bigger Picture for SMA Patients

Despite three approved therapies, unmet need in SMA remains substantial. Current treatments can't restore motor neurons that have already died, which means early treatment is critical but not sufficient. Adults living with SMA still face significant challenges in respiratory function, nutrition, orthopedic health, and daily mobility. The existing drugs are also imperfect in practical terms: Spinraza requires repeated spinal injections, and Zolgensma has age and eligibility restrictions.

Apitegromab doesn't solve all of these problems, but it opens a genuinely new front. For the first time, doctors can pair a treatment that addresses the genetic cause of SMA with one that tackles the muscular consequence. It's a two-pronged strategy that the SMA community has been waiting for.

What This Means for the Myostatin Field

It's tempting to call this a vindication of the entire myostatin inhibitor class. It's not, exactly. What Scholar Rock proved is narrower and arguably more interesting: that a highly selective approach to myostatin inhibition, tested in the right disease, can produce real functional gains.

The graveyard of failed myostatin programs wasn't wrong about the biology. Blocking muscle growth inhibition is a sound idea. Those programs were wrong about the execution; they used blunt tools in tough diseases. Scholar Rock sharpened the tool and picked a smarter fight.

For patients with SMA, the practical impact is straightforward. They now have a therapy that goes after the part of their disease that existing drugs can't reach. And for the broader neuromuscular field, Scholar Rock just proved that the myostatin story isn't over. It was just getting started with the wrong chapter.